Krystal Biotech, Inc. KRYS Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s unrealized losses on investments (before tax)?
- Krystal Biotech, Inc. (KRYS) reported unrealized losses on investments (before tax) of $686K in Q1 2026.
- How has Krystal Biotech, Inc.'s unrealized losses on investments (before tax) changed year-over-year?
- Krystal Biotech, Inc.'s unrealized losses on investments (before tax) increased by 274.9% year-over-year, from $183K to $686K.
- What is the long-term trend for Krystal Biotech, Inc.'s unrealized losses on investments (before tax)?
- Over 4 years (2021 to 2025), Krystal Biotech, Inc.'s unrealized losses on investments (before tax) has grown at a -54.1% compound annual growth rate (CAGR), from $180K to $8K.